Schrodinger Q3 revenue beats expectations on milestone payment

What happened

Schrodinger’s third-quarter revenue rose 19% year over year and beat analyst expectations, helped by a milestone payment from Structure Therapeutics. Its net loss widened from the prior year, while the company raised its 2026 annual contract value and drug discovery revenue outlooks.

Confirmed

Global impact / market context

The revenue beat was primarily driven by a milestone payment from Structure Therapeutics, so it may not indicate the same pace of recurring growth. Higher 2026 guidance could support expectations for future software and drug discovery revenue, while lower planned expenses could limit cash use.

Analyst inference

The results combine stronger reported revenue with a wider net loss, while software gross margin, meaning revenue left after software delivery costs, fell 2% during a shift to hosted licenses. Investors therefore have to weigh growth guidance against losses, cost changes, and the milestone payment's contribution.

Analyst inference

What to watch

1. Check whether later quarters show drug discovery revenue growth beyond milestone payments; repeated customer-related revenue would provide stronger evidence that growth is continuing. Analyst inference
2. Compare the raised 2026 annual contract value guidance with reported software performance as the company continues shifting customers to hosted licenses, a delivery model that lowered software gross margin. Confirmed
3. Track whether operating expenses remain below 2025 levels and whether the wider net loss narrows, since those outcomes affect how quickly the company uses cash. Analyst inference

Evidence

• Original source link unavailable